Erasca, Inc.

Erasca, Inc. (ERAS) Annual Report Summary for Fiscal Year Ended December 31, 2025

Erasca, Inc. (ERAS), a clinical-stage oncology company listed on the Nasdaq Global Select Market, is racing to discover, develop, and commercialize new cancer medicines. This summary highlights its performance, strategic advancements, and financial health for the fiscal year ended December 31, 2025, as detailed in its SEC 10-K filing. As a 'Non-accelerated filer,' 'Smaller reporting company,' and 'Emerging growth company,' Erasca benefits from streamlined reporting requirements, a common practice for companies at its current stage of development and market size.

Business Overview Erasca is a clinical-stage oncology company committed to finding, developing, and bringing to market innovative cancer treatments. It advances its pipeline of potential cancer therapies through both internal research and development and strategic partnerships and licensing deals.

Financial Performance Erasca's financial results for 2025 show a net loss of approximately $145.2 million, an increase from the $120.5 million net loss reported in 2024.

• Revenue: The company earned $8.7 million in collaboration revenue during 2025, primarily from upfront payments and milestone achievements from licensing agreements.
• Research & Development (R&D) Expenses: R&D expenses rose to $110.3 million in 2025 from $95.8 million in 2024.
• General & Administrative (G&A) Expenses: G&A expenses reached $34.9 million in 2025, up from $28.1 million in 2024.

Management Discussion and Analysis (MD&A) Highlights The higher net loss in 2025 largely resulted from increased research and development (R&D) activities as Erasca advanced its clinical pipeline. R&D expenses grew due to the progress of lead drug candidates like ERAS-007 and ERAS-810. The company also expanded its pipeline through new licensing agreements (e.g., Novartis, Medshine, NiKang, Joyo) and the strategic acquisition of Asana Biosciences. General and administrative expenses climbed to support Erasca's expanding operations, corporate functions, and capital raising initiatives. Collaboration revenue significantly contributed to the company's finances, mainly from upfront payments and milestone achievements from strategic licensing agreements, including a notable $50.0 million upfront payment from Novartis Pharma AG. Management continues to prioritize pipeline advancement and strategic collaborations to speed up the development of new cancer therapies.

Financial Health Erasca maintained a strong financial position, holding approximately $285.4 million in cash, cash equivalents, and marketable securities as of December 31, 2025. This cash reserve is expected to fund operations into late 2027, providing significant financial stability. The company primarily finances its activities through equity offerings and collaboration agreements, reporting no significant long-term debt at year-end 2025. Erasca effectively accessed capital markets during the period, completing a private placement, underwritten public offerings, and an "At-The-Market" (ATM) offering. A subsequent offering in early 2026 further strengthened its financial standing.

Future Outlook Looking ahead, Erasca will continue to prioritize advancing its clinical pipeline, especially its lead programs ERAS-007 (an ERK1/2 inhibitor) and ERAS-810 (a CNS-penetrant EGFR inhibitor). The company intends to use its strategic partnerships, like the key collaboration with Novartis for ERAS-999, to speed up the development and potential market launch of innovative cancer therapies. Erasca expects to share more updates on clinical trial progress and pipeline achievements in the next fiscal year, underscoring its dedication to delivering new cancer treatments to patients.

Competitive Position The oncology market is intensely competitive, marked by rapid technological advancements, extensive research and development, and substantial financial investments from many players. Erasca competes with large pharmaceutical companies, established biotechnology firms, and other emerging biopharmaceutical companies. Many of these competitors possess greater financial, technical, and human resources.

Competition spans all stages of drug development, from discovery and preclinical research to clinical trials, regulatory approval, and commercialization. Key competitive factors include the effectiveness, safety, and convenience of potential drugs, speed to market, strength of intellectual property protection, and the ability to attract and retain skilled talent and secure funding. Erasca's competitive strategy focuses on novel mechanisms of action and specific oncology targets. It builds a diverse pipeline through internal development and strategic collaborations, leveraging its scientific expertise to address critical unmet medical needs in cancer treatment.

Risk Factors Investing in Erasca carries significant risks, typical for clinical-stage biotechnology companies:

• Clinical Trial Success: The success of Erasca's potential drugs is highly uncertain and hinges on the results of ongoing and future clinical trials. Failure at any stage could severely impact the company's value.
• Regulatory Approval: Gaining regulatory approvals for new drugs is a long, costly, and unpredictable process. There is no guarantee Erasca's candidates will receive approval.
• Need for Future Funding: Despite recent capital raises, Erasca will need substantial additional funding to complete the development and commercialization of its drug candidates. Future financing might not be available on favorable terms or at all, which could significantly affect its operations.
• Competition: The highly competitive oncology market includes many large pharmaceutical and biotechnology companies developing similar therapies. This intense competition could limit Erasca's market share or pricing power.
• Intellectual Property: Erasca's success relies on its ability to protect its intellectual property and operate without infringing on others' rights. Challenges to its patents or an inability to secure new patents could negatively impact its business.